Molecular Partners AG (XSWX:MOLN) Sale Of Investment : CHF319.44 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Sale Of Investment?

Molecular Partners AG's sale of investment for the three months ended in Dec. 2023 was CHF68.16 Mil. It means Molecular Partners AG gained CHF68.16 Mil from selling investments. Molecular Partners AG's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was CHF319.44 Mil.

Compared with last quarter (CHF89.56 Mil in Sep. 2023 ), Molecular Partners AG gained less money from selling investments in Dec. 2023 (CHF68.16 Mil).

Molecular Partners AG Sale Of Investment Historical Data

The historical data trend for Molecular Partners AG's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Sale Of Investment Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

Get a 7-Day Free Trial

56.63

52.77

67.88

199.22

319.44

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sale Of Investment	Get a 7-Day Free Trial															68.80	87.58	74.14	89.56	68.16

Molecular Partners AG Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF319.44 Mil.

Molecular Partners AG Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.